Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Abstract

Breast cancer characterized by overexpression of human epidermal growth factor receptor 2 (HER2) has been associated with more aggressive disease progression and a poorer prognosis. Although an improved understanding of breast cancer pathogenesis and the role of HER2 signaling has resulted in significant survival improvements in the past 20 years, resistance to HER2-targeted therapy remains a concern. A number of strategies to prevent or overcome resistance to HER2-targeted therapy in breast cancer are being evaluated. This article provides a comprehensive review of (a) the role of HER2 signaling in breast cancer pathogenesis, (b) potential receptor and downstream therapeutic targets in breast cancer to overcome resistance to HER2-targeted therapy, and (c) clinical trials evaluating agents targeting one or more members of the HER family and/or downstream pathways for the treatment of breast cancer, with a focus on metastatic disease.

• Authors: Zeynep Eroglu, Tomoko Tagawa, George Somlo
• Journal: The oncologist (Oncologist) Vol. 19 Issue 2 Pg. 135-50 (Feb 2014) ISSN: 1549-490X [Electronic] England
• PMID: 24436312 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Quinazolines
• Lapatinib
• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Breast Neoplasms (drug therapy, enzymology)
• Clinical Trials, Phase III as Topic
• Disease Progression
• Drug Resistance, Neoplasm
• Female
• Humans
• Lapatinib
• Molecular Targeted Therapy
• Quinazolines (administration & dosage)
• Randomized Controlled Trials as Topic
• Receptor, ErbB-2 (antagonists & inhibitors, biosynthesis)
• Signal Transduction
• Trastuzumab